The adiponutrin (PNPLA3) variant increases the risk of developing end-stage liver cirrhosis but does not affect survival in patients with cirrhosis

Background: The common adiponutrin (PNPLA3) variant (p.I148 M) has been associated with the development and progression of chronic liver disease such as NASH and ASH as well as HCC (Liu et al. J Hepatol 2014). Recently we have described that the p.I148 M mutation is also associated with increased liver stiffness (Krawczyk et al. J Hepatol 2011). Currently there is no data available on the effect of this variant and survival in patients with advanced liver disease. We therefore tested whether the p.I148 M polymorphism is associated with mortality in patients with advanced liver cirrhosis. Patients and methods: Th…